vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and IAMGOLD CORP (IAG). Click either name above to swap in a different company.
IAMGOLD CORP is the larger business by last-quarter revenue ($724.2M vs $156.4M, roughly 4.6× BIOCRYST PHARMACEUTICALS INC).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Iamgold Corporation is a Canadian company that owns and operates gold mines in Burkina Faso and Canada. Headquartered in Toronto, the company was incorporated in 1990, and went public on the Toronto Stock Exchange in 1996, with additional shares being listed on the New York Stock Exchange beginning in 2005. The company formerly owned or had stakes in the Sadiola and Yatela gold mines in Mali, the Mupane gold mine in Botswana, the Niobec niobium mine in Quebec, as well as a royalty in the Diav...
BCRX vs IAG — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $724.2M |
| Net Profit | — | — |
| Gross Margin | — | 35.4% |
| Operating Margin | 13.6% | — |
| Net Margin | — | — |
| Revenue YoY | 7.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | — | ||
| Q3 25 | $159.4M | — | ||
| Q2 25 | $163.4M | $724.2M | ||
| Q1 25 | $145.5M | $338.9M | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | — | ||
| Q2 24 | $109.3M | $465.0M |
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $32.0K | — | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $-12.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | 35.4% | ||
| Q1 25 | 96.9% | 31.2% | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | 15.0% |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | — | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 8.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | — | ||
| Q2 24 | -11.6% | — |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $465.1M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | — | ||
| Q3 25 | $-387.9M | — | ||
| Q2 25 | $-421.6M | — | ||
| Q1 25 | $-451.9M | — | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | — | ||
| Q2 24 | $-475.6M | — |
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | — | ||
| Q3 25 | $446.4M | — | ||
| Q2 25 | $457.2M | — | ||
| Q1 25 | $480.0M | — | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | — | ||
| Q2 24 | $472.4M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
IAG
Segment breakdown not available.
